CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma

Inclusion Criteria

• •The subject must meet all of the following criteria:
• •1. 18-65 years old;
• •2. Relapsed or refractory T-NHLs, including peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), ALK-positive ALCL, ALK-negative Image result for anaplastic large cell lymphoma (ALCL), enteropathy-related T-cell lymphoma, hepatosplenic T-cell lymphoma, etc.;
• •3. Previously received ≥2 lines of treatment without a complete response;
• •4. Immunohistochemical detection of tumor cells CD147 positive;
• •5. ECOG score 0-2;
• •6. The collection of mononuclear cells can be performed upon the judgment of the researcher;
• •7. No contraindications for allogeneic hematopoietic stem cell transplantation (AlloHCT);
• •8. Have donors for AlloHCT;
• •9. Agree for sequential treatment of AlloHCT;
• •10. Without serious organ dysfunction in 2 weeks before CAR-T infusion:
• •1. Heart: without arrhythmia, LVEF≥50%, and without pericardial effusion; without heart failure (NYHA class III or IV) within12 months before CAR-T infusion; without myocardial infarction within 12 months before CAR-T infusion; without long-QT syndrome or secondary QT interval prolongation;
• •2. Liver: ALT\<2 times the upper limit of normal (ULN) and TBIL\<1.5 times ULN, without active hepatitis;
• •3. APTT and PT\<1.5 times ULN;
• •4. Kidney: Serum creatinine \<1.5 mg/dl; or if the serum creatinine exceeds the upper limit, eGFR (CKD-EPI formula) needs to be \> 50 ml/min;
• •5. Fingertip blood oxygen saturation ≥ 92%.
• •11. Estimated survival ≥ 3 months;
• •12. Sexually active patients must be willing to use an effective method of birth control during the study period and within 6 months after the study ending, and male partners should use condoms;
• •13. The patient is willing to join this clinical trial and sign an informed consent.